Angina Pectoris

7
Pipeline Programs
5
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
ASPRUZYO SPRINKLEApproved
ranolazine
Unknown Company
Anti-anginal [EPC]oral2022

Competitive Landscape

5 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
3 programs
3
RanolazinePhase 41 trial
RanolazinePhase 41 trial
RanolazinePhase 4
Active Trials
NCT01425359Completed949Est. Oct 2012
NCT01334203Withdrawn0Est. Dec 2012
GSK
GSKLONDON, United Kingdom
1 program
1
RosiglitazonePhase 41 trial
Active Trials
NCT00225342Withdrawn60
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Succinate MetoprololPhase 4Small Molecule1 trial
Active Trials
NCT01213173Completed251Est. Sep 2011
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Lacidipine, low dosePhase 21 trial
Active Trials
NCT02232607Completed283
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Tele-medicine platformN/A1 trial
Active Trials
NCT04325867UnknownEst. Oct 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesRanolazine
Gilead SciencesRanolazine
AstraZenecaSuccinate Metoprolol
Boehringer IngelheimLacidipine, low dose
T-TherapeuticsTele-medicine platform

Clinical Trials (6)

Total enrollment: 1,543 patients across 6 trials

NCT00225342GSKRosiglitazone

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

60 patients
Phase 4Withdrawn
NCT01425359Gilead SciencesRanolazine

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Start: Sep 2011Est. completion: Oct 2012949 patients
Phase 4Completed
NCT01334203Gilead SciencesRanolazine

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

Start: May 2011Est. completion: Dec 20120
Phase 4Withdrawn
NCT01213173AstraZenecaSuccinate Metoprolol

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

Start: Oct 2010Est. completion: Sep 2011251 patients
Phase 4Completed
NCT02232607Boehringer IngelheimLacidipine, low dose

Efficacy and Safety of Lacidipine in Chronic Stable Angina

Start: Apr 1998283 patients
Phase 2Completed
NCT04325867T-TherapeuticsTele-medicine platform

Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19

Start: Mar 2020Est. completion: Oct 2020
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space